Continuous lenalidomide treatment for newly diagnosed multiple myeloma

Continuous lenalidomide treatment for newly diagnosed multiple myeloma

Palumbo A;Hajek R;Delforge M;Kropff M;Petrucci MT;Catalano J;Gisslinger H;Wiktor-Jędrzejczak W;Zodelava M;Weisel K;Cascavilla N;Iosava G;Cavo M;Kloczko J;Bladé J;Beksac M;Spicka I;Plesner T;Radke J;Langer C;Ben Yehuda D;Corso A;Herbein L;Yu Z;Mei J;Jacques C;Dimopoulos MA; ;;
The New England journal of medicine 2012 Vol. 366 pp. -
326
a2012thecontinuous

Abstract

MPR-R significantly prolonged progression-free survival in patients with newly diagnosed multiple myeloma who were ineligible for transplantation, with the greatest benefit observed in patients 65 to 75 years of age. (Funded by Celgene; MM-015 ClinicalTrials.gov number, NCT00405756.).

Keywords

Administration National Center for Biotechnology Information NCBI NLM MEDLINE humans pubmed abstract nih national institutes of health national library of medicine research support non-u.s. gov't female male aged Comparative Study 80 and over Clinical Trial Phase III Randomized Controlled Trial Double-Blind Method Multicenter Study follow-up studies neutropenia / chemically induced induction chemotherapy antineoplastic combined chemotherapy protocols / adverse effects disease-free survival prednisone / adverse effects oral neoplasms kaplan-meier estimate maintenance chemotherapy antineoplastic combined chemotherapy protocols / therapeutic use* prednisone / administration & dosage* initials='g' affs=[] is_editor=false suffix=none equal_contrib=false) initials='jp' initials='ag' initials='j' initials='a' initials='h' initials='am' initials='b' initials='n' initials='p' initials='k' author(firstnames='j' author(firstnames='g' author(firstnames='h' author(firstnames='a m' author(firstnames='p' author(firstnames='a' initials='d' affs=[]) initials='s' initials='m' initials='o' initials='f' initials='i' initials='r' initials='e' initials='v' author(firstnames='s' author(firstnames='n' author(firstnames='t' initials='t' author(firstnames='m' author(firstnames='d' author(firstnames='e' author(firstnames='k' author(firstnames='r' author(firstnames='v' initials='fj' initials='js' initials='ml' initials='z' equal_contrib=false)] lastname='mollee' lastname='prince' lastname='horvath' lastname='greil' lastname='van droogenbroeck' lastname='schots' author(firstnames='f' author(firstnames='z' author(firstnames='i' author(firstnames='o' pmid:22571200 doi:10.1056/nejmoa1112704 antonio palumbo roman hajek collabauthor(name='mm-015 investigators' investigators=[author(firstnames='b' lastname='augustson' lastname='joshua' lastname='spencer' lastname='taylor' author(firstnames='a g' lastname='gastl' lastname='ludwig' lastname='iskrov' lastname='uss' lastname='fillet' lastname='maisnar' lastname='scudla' lastname='gregersen' lastname='attal' author(firstnames='j p' lastname='fermand' lastname='jaccard' lastname='macro' author(firstnames='j -f' lastname='rossi' initials='j-' lastname='dölken' lastname='engelhardt' lastname='goldschmidt' lastname='knop' lastname='niederwieser' lastname='crotty' lastname='nagler' lastname='rowe' lastname='shpilberg' lastname='cafro' lastname='caravita' lastname='foa' lastname='gobbi' lastname='zweegman' lastname='dmoszynska' lastname='hellmann' author(firstnames='a b' lastname='skotnicki' initials='ab' lastname='abdulkadyrov' lastname='domnikova' lastname='osmanov' lastname='rossiev' lastname='rukavistin' lastname='alegre' author(firstnames='f j' lastname='capote' author(firstnames='m l' lastname='martino' author(firstnames='j s' lastname='miguel' lastname='ahlgren' lastname='bauer' lastname='stenner' lastname='cagirgan' lastname='schey' lastname='yong' lastname='kaplan' lastname='kyeting' lastname='lysa' lastname='maslyak' lastname='pylypenko' lastname='tretyak' lenalidomide melphalan / administration & dosage* melphalan / adverse effects multiple myeloma / drug therapy* multiple myeloma / mortality second primary / epidemiology thalidomide / administration & dosage thalidomide / adverse effects thalidomide / analogs & derivatives*

Citation

ID: 269069
Ref Key: a2012thecontinuous
Use this key to autocite in SciMatic or Thesis Manager

References

Blockchain Verification

Account:
NFT Contract Address:
0x95644003c57E6F55A65596E3D9Eac6813e3566dA
Article ID:
269069
Unique Identifier:
Network:
Scimatic Chain (ID: 481)
Loading...
Blockchain Readiness Checklist
Authors
Abstract
Journal Name
Year
Title
5/5
Creates 1,000,000 NFT tokens for this article
Token Features:
  • ERC-1155 Standard NFT
  • 1 Million Supply per Article
  • Transferable via MetaMask
  • Permanent Blockchain Record
Blockchain QR Code
Scan with Saymatik Web3.0 Wallet

Saymatik Web3.0 Wallet